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Abstract
Background: Whilst cannabis commercialization is occurring rapidly guided by highly individualistic public
narratives, evidence that all congenital anomalies (CA) increase alongside cannabis use in Canada, a link with 21
CA’s in Hawaii, and rising CA’s in Colorado indicate that transgenerational effects can be significant and impact
public health. It was therefore important to study Northern New South Wales (NNSW) where cannabis use is high.
Methods: Design: Cohort. 2008–2015. Setting: NNSW and Queensland (QLD), Australia. Participants. Whole
populations. Exposures. Tobacco, alcohol, cannabis. Source: National Drug Strategy Household Surveys 2010, 2013.
Main Outcomes. CA Rates. NNSW-QLD comparisons. Geospatial and causal regression.
(Continued on next page)
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Results: Cardiovascular, respiratory and gastrointestinal anomalies rose with falling tobacco and alcohol but rising
cannabis use rates across Queensland. Maternal age NNSW-QLD was not different (2008–2015: 4265/22084 v. 96,
473/490514 > 35 years/total, Chi.Sq. = 1.687, P = 0.194). A higher rate of NNSW cannabis-related than cannabisunrelated defects occurred (prevalence ratio (PR) = 2.13, 95%C.I. 1.80–2.52, P = 3.24 × 10− 19). CA’s rose more potently
with rising cannabis than with rising tobacco or alcohol use. Exomphalos and gastroschisis had the highest NNSW:
QLD PR (6.29(2.94–13.48) and 5.85(3.54–9.67)) and attributable fraction in the exposed (84.11%(65.95–92.58%) and
82.91%(71.75–89.66%), P = 2.83 × 10− 8 and P = 5.62 × 10− 15). In multivariable geospatial models cannabis was
significantly linked with cardiovascular (atrial septal defect, ventricular septal defect, tetralogy of Fallot, patent
ductus arteriosus), genetic (chromosomal defects, Downs syndrome), gastrointestinal (small intestinal atresia), body
wall (gastroschisis, diaphragmatic hernia) and other (hypospadias) (AVTPCDSGDH) CA’s. In linear modelling cannabis
use was significantly linked with anal stenosis, congenital hydrocephalus and Turner syndrome (ACT) and was
significantly linked in borderline significant models (model P < 0.1) with microtia, microphthalmia, and transposition
of the great vessels. At robust and mixed effects inverse probability weighted multivariable regression cannabis was
related to 18 defects. 16/17 E-Values in spatial models were > 1.25 ranging up to 5.2 × 1013 making uncontrolled
confounding unlikely.
Conclusions: These results suggest that population level CA’s react more strongly to small rises in cannabis use
than tobacco or alcohol; cardiovascular, chromosomal, body wall and gastrointestinal CA’s rise significantly with
small increases in cannabis use; that cannabis is a bivariate correlate of AVTPCDSGDH and ACT anomalies, is robust
to adjustment for other substances; and is causal.
Keywords: Cannabis, Teratology, Cardiovascular defects, Atrial septal defect, Gastroschisis, Exomphalos, Genotoxicity

Background
With major tobacco companies entering the cannabis
market it is clear that cannabis commercialization is well
under way [1]. Whilst much of the discussion relating to
cannabis use and cannabis control is notably selfreferential recent epidemiological reports suggest that intergenerational effects may be both significant and powerful enough to impact population-level health outcomes.
A recent report on Canada demonstrated that total congenital defects were three times more common in the
northern Territories which smoked more cannabis than
the Provinces and that the association was robust to socioeconomic adjustment [2]. A recent study from Colorado
across the period of cannabis legalization showed that
many defects rose parallel to increased cannabis consumption including all chromosomal defects (ACD), Downs
syndrome and several cardiovascular defects including
atrial septal defect (ASD) and patent ductus arteriosus
(PDA), common defects which had not been previously
linked with prenatal cannabis exposure (PCE) [3]. It was
calculated that in Colorado over 11,000 extra defects occurred 2000–2014 related to increased cannabis use [3].
An Hawaiian study found that 21 defects were increased
in mothers who were exposed only to cannabis [4].
Whilst some of these studies have used sophisticated
geospatial modelling techniques [2] all epidemiological
research is fundamentally associational in nature. However similar findings elsewhere strengthens the evidence
base.

Northern New South Wales (NNSW, NSW) is a well
known drug using and cannabis cultivation area 760 km
from Sydney but only 180 km from tertiary pediatric
care centres in Brisbane and 111 km from Southport
both in Queensland (QLD). Although lying within New
South Wales administratively many of its neonatal CA’s
are evacuated to tertiary pediatric hospitals in Queensland under the Neonatal Retrieval Scheme (NRS) [5] and
their data thus appears in Queensland statistics. This
therefore presents an ideal opportunity to directly compare NNSW and Queensland neonatal epidemiology.
Our hypothesis was that cannabis use would be associated with increased congenital anomalies and was formulated prior to study commencement.

Methods
Data

Data on congenital anomaly rates for Queensland Health
service areas including northern New South Wales was
taken from the Congenital Anomaly Linked File (CALF)
from Queensland Health [6]. Annual data by area has
not been publicly released. Data on maternal age was
from the QLD and NSW annual Mothers and Babies reports [7, 8]. CALF data includes numbers, rates and confidence intervals for the data. Drug use data for last
month cigarette use, last month binge alcohol and last
year cannabis use by area was obtained from the Australian Institute of Health and Welfare from the National
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Drug Strategy Household Survey (NDSHS) 2010 and
2013 [9] and averaged to obtain a mean rate by area
across this period pursuant to our custom data request.
Data was matched manually between drug use and congenital anomaly datasets. Areal shapefiles were taken
from the Australian Government national website [10].
The northern coastal area of NSW was added on to the
Queensland Health shapefile. This depiction of the
NNSW catchment area is illustrative only and not
intended to be exact as the geographic boundaries of the
NRS are not defined [5].
Congenital anomalies were defined as cannabis related or not based on a literature review and recent
reports [2, 3, 11–13] particularly [4].

map was used to calculate the geospatial weights matrix
for spatial regression.
Geospatial regression was performed with the spreml function from package splm [13, 16] using the derived spatial
weights matrix. Spatial models may include the parameters
phi, psi, rho and lambda for random effects in the error term,
serial autocorrelation in the residuals, spatial errors, and
autocorrelation in the spatial errors respectively. All spatial
models used a full error structure of Kapoor Kelejian and
Prucha [17] and had serially correlated remainder errors and
random effects (sem2srre). The appropriateness of this error
structure was formally tested by substituting various alternative forms and comparing results including the maximum
likelihood ratio at model optimization (LogLik in the tables)
and spatial Hausman tests and by examining the significance
of the final model parameters [18]. Models were spatially
lagged and not lagged as indicated.
Inverse probability weights (IPW) were derived with the
ipw package in R using cannabis use as the exposure of
interest, tobacco in the numerator and tobacco and alcohol in the denominator. IPW weights were then used in
robust regression models conducted in the R package survey, and in mixed effects models in the R package nlme to
generate datasets pseudo-randomized for cannabis exposure. This allowed causal relationships to be assessed. EValues were calculated with the R package EValue to
quantify the degree of association some unmeasured confounder would require with both dependent and independent variables to explain away the observed effect.
It was necessary to use various regression model structures for several reasons. Only spatial models can capture
the spatial effects amongst the data, however they cannot
be inverse probability weighted, so that causality can not
be studied directly from them. Spatial models do provide
a model variance which allows e-Values to be calculated
from them. Robust marginal structural models can be inverse probability weighted, but do not provide model
standard deviations so that e-Values cannot be calculated
from them directly. Mixed effects models can be inverse
probability weighted and also provide model standard deviations, but do not capture spatial effects and are also not
robust in design. Hence for a full picture and understanding of the causal and spatial processes involved one needs
to consider output from all of these various model structures together with their applicable e-Values.
For all regression models model reduction was by the
classical method with sequential deletion of the least significant term. Missing data was casewise deleted at multivariable regression. P < 0.05 was considered significant.
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Sample characteristics

The samples were whole population samples and included
all births in all health regions of Queensland. Hence inclusion and exclusion criteria were not applied as the samples
were complete population samples. Sample capture in
Northern New South Wales (NSW) appears to have been
incomplete as some birth defects were not captured in the
Queensland data and were managed in New South Wales.
Hence the Northern New South Wales rates described in
the present report clearly represents underestimates of the
total rates. As the NSW and Queensland datasets are not
directly comparable it is not possible to directly merge the
two datasets to form a complete picture. This study limitation is discussed further in the limitations paragraph of
the Discussion.
Statistics

Data was processed in RStudio version 1.2.1335 based
on R version 3.6.1 on 16th April 2020. Two-by-two tables were analyzed in package epiR using epi.2by2.
Graphs were drawn with R-Base and ggplot2 [14] and in
Microsoft Excel. Maps were drawn using the R packages
ggplot2 and sf (“simple features”) [14, 15]. The software
is freely available online and is directly loaded from inside RStudio software downloaded from the Comprehensive “R” Archive Network (CRAN). Licences for all R
software are freely available with the R packages sourced
from CRAN and its various mirrors internationally. Principal component analysis was conducted using the psych
package. Linear regression was performed in Base-R.
Batch extraction of all linear model coefficients by different defects was performed with broom and purrr packages. Correction of P-values for multiple testing was
applied using the corrections of Holm, Bonferroni, Benjamini and Yekutieli, False Discovery Rate and Hommel
as indicated. Links between neighbouring areas sharing
an edge or corner (“queen”-relationships by analogy with
chess moves) were derived with the poly2nb function
from spdep and edited as indicated. This neighbourhood

Data availability statement

Data including R software code have been made available online in the Mendeley Data Repository at https://
doi.org/10.17632/cjzfyktz5m.1.
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Table 1 Results of geospatial additive regression by selected congenital anomalies - spatial error models
Parameters
Parameter

Model
Estimate (C.I.)

P-Value

Parameters

Value

P-Value

INTERACTIVE MODELS
spreml(Atrial_Septal_Defects ~ Tobacco * Binge_Alcohol * Cannabis)
Atrial_Septal_Defect
Binge_Alcohol: Cannabis

−0.58 (− 1.12, − 0.04)

0.0376

phi

0.0101

NA

Tobacco: Binge_Alcohol: Cannabis

0.03 (0, 0.06)

0.0417

psi

9.1E-08

1.0000

Tobacco: Cannabis

−0.09 (−0.18, 0)

0.0423

rho

−0.9960

0.0037

Tobacco: Binge_Alcohol: Cannabis

−0.01 (− 0.01, − 0.01)

0.0007

phi

0.0890

NA

Binge_Alcohol: Cannabis

0.05 (0.02, 0.08)

0.0021

psi

2.2E-05

0.9999

Tobacco: Cannabis

0.02 (0.01, 0.03)

0.0047

rho

−0.9805

0.0058

Tobacco: Binge_Alcohol

0.02 (0, 0.04)

0.0184

Cannabis

7.26 (3.21, 11.31)

0.0004

phi

0.0095

0.9964

Binge_Alcohol

7.33 (3.15, 11.51)

0.0006

psi

−1.7E-07

1.0000

Binge_Alcohol: Cannabis

−2.07 (−3.26, − 0.88)

0.0006

rho

0.9660

<2e-16

Tobacco: Cannabis

−0.22 (− 0.37, − 0.07)

0.0041

Tobacco: Binge_Alcohol: Cannabis

0.06 (0.02, 0.1)

0.0051

Tobacco

0.17 (0.04, 0.3)

0.0091

Binge_Alcohol: Cannabis

0.03 (0.02, 0.04)

3.4E-05

phi

0.0571

NA

Binge_Alcohol

−2.33 (−3.7, − 0.96)

0.0008

psi

3.6E-05

0.9998

rho

−0.6662

0.0626

CHROMOSOMAL_Defects

Diaphragmatic_Hernia

Downs Syndrome

Gastroschisis
Cannabis

0.07 (0.03, 0.11)

0.0030

phi

0.0144

NA

psi

1.8E-05

0.9999

rho

−0.2503

0.5520

Hypospadias
Tobacco: Cannabis

−0.13 (− 0.22, − 0.04)

0.0062

phi

0.0027

NA

Tobacco: Binge_Alcohol: Cannabis

0.04 (0.01, 0.07)

0.0084

psi

4.3E-05

0.9999

Tobacco: Binge_Alcohol

−0.35 (− 0.66, − 0.04)

0.0266

rho

−0.2080

0.6705

Tobacco

1.13 (0.11, 2.15)

0.0304

Cannabis

0.24 (0.01, 0.47)

0.0358

phi

0.0109

NA

Binge_Alcohol: Cannabis

−0.06 (−0.12, 0)

0.0526

Patent_Ductus_Arteriosus

psi

1.8E-06

1.0000

rho

−0.9998

0.0022

phi

0.0100

NA

psi

1.3E-07

1.0000

rho

−0.0089

0.9825

phi

0.1102

0.9963

psi

5.7E-05

0.9998

rho

0.3074

0.3382

Small Intestinal Stenosis / Atresia
Cannabis

0.02 (0.01, 0.03)

0.0003

Tetralogy_Fallot
Cannabis

0.09 (0.04, 0.14)

0.0007
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Table 1 Results of geospatial additive regression by selected congenital anomalies - spatial error models (Continued)
Parameters
Parameter

Model
Estimate (C.I.)

P-Value

Parameters

Value

P-Value

Tobacco: Cannabis

−0.11 (− 0.21, − 0.01)

0.0328

phi

0.4947

NA

Tobacco: Binge_Alcohol: Cannabis

0.03 (0, 0.06)

0.0372

psi

1.2E-04

0.9997

Cannabis

2.93 (−0.23, 6.09)

0.0692

rho

−1.0000

0.0306

Binge_Alcohol: Cannabis

−0.85 (−1.79, 0.09)

0.0750

Ventricular_Septal_Defect

Ethics

This study was approved by the Human Research Ethics
Committee of the University of Western Australia on
15th April 2020 (No. RA/4/20/4724).

Results
Input data is shown in an online supplementary csv file.
Supplementary Table 1 provides comparative congenital
anomaly data between QLD and NSW by both numbers
and rates including defect relationship to cannabis [6]. Denominator data was calculated from the numbers and

rates supplied in that file. It was verified from the annual
QLD Health Mothers and Babies reports 2008–2015
which show 509,095 births in this period [8]. The “Interstate and Overseas” designation in the CALF file includes
offshore islands such as Christmas, Norfolk, Cocos and
Lord Howe Islands which together have a population of
4518. The prime catchment area of the NRS is Northern
NSW which has a population of 296,531 [10]. Hence only
1.5% of the population in this designation is likely to come
from outside NNSW. The view that the “Interstate and
Overseas” designation refers primarily to NNSW is

Fig. 1 Trend analysis over time of (a) drugs and (b) various congenital defects and defect classes
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Fig. 2 Choropleth maps of congenital anomaly class rates across QLD and NNSW. High rates are shown in yellow and low rates in dark blue.
Maps were drawn using R package “sf” [15]

Fig. 3 Choropleth maps of various chromosomal anomaly rates across QLD and NNSW. High rates are shown in yellow and low rates in dark
blue. Maps were drawn using R package “sf” [15]
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Fig. 4 Confidence Intervals of cannabis-related and cannabis-unrelated congenital anomalies for (a) common, (b) intermediate frequency and (c)
rare congenital anomalies

confirmed by QLD Health Ministerial correspondence
(Minister Steven Miles, 05/04/2018). The denominator
figure calculated for NNSW in this manner is 4800 births.
It should be noted that NNSW birth defect data also
appears in NSW Health records [7]. One notes that the
rates of congenital anomalies reported for this region in
the NSW Mothers and Babies reports are about half

those of the rest of the state. This is presumably related
to the relocation of many cases into Queensland through
the NRS. Queensland congenital anomaly rates are much
higher than those reported elsewhere so it is not possible
simply to combine NSW and QLD Health reports.
Therefore this report is limited to consideration of the
QLD Health CALF file only.

Fig. 5 Confidence Intervals of rare cannabis-related and cannabis-unrelated congenital anomalies in more detail

Reece and Hulse BMC Pharmacology and Toxicology

(2020) 21:75

Fig. 6 Relative Rates of Congenital Anomalies in Queensland v NNSW

Fig. 7 Relative Rate Ratios between Queensland and NNSW by relationship to Cannabis
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Fig. 8 Log (Relative Rate Ratios) between Queensland and NNSW by relationship to Cannabis

Drug use data is shown in Supplementary Table 2. It
is noteworthy that the Richmond-Tweed NNSW area
has a middle ranking for tobacco and alcohol use, but a
first ranking for cannabis use.
Maternal age is a major factor bearing on congenital
anomaly rates and it is known to be strongly linked with
chromosomal anomaly rates. For years 2008–2015 4265/
22084 (19.31%) births in NNSW were to mothers > 35
years compared to 96,493/490514 (19.67%; 18,581 missing maternal age data) in Queensland (Chi.Sq. = 1.687,
df = 1, P = 0.194). This compares to 22,133/92242

(23.9%) of 2012 births in the rest of NSW (Chi.Sq. =
98.954, df = 1, P = 4.33 × 10− 10) indicating that NNSW
mothers are younger in than elsewhere in NSW.
Interestingly CALF Table 1 shows rises in the rates of
several defects (Fig. 1) including CVS defects, atrial septal defect (ASD) and ventricular septal defect (VSD)
which are highly significant (Supplementary Table 3). Intriguingly the mean incidence of daily smoking tobacco
and high risk alcohol use dropped across this period and
annual cannabis use rose from 10.5 to 11.3%. The principal component of the combination of cardiovascular,

Fig. 9 Prevalence Ratios (a) cannabis-related and (b) cannabis-unrelated congenital anomalies
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Fig. 10 Attributable Fraction in the Exposed for (a) cannabis-related and (b) cannabis-unrelated congenital anomalies

gastrointestinal and respiratory anomalies also rose significantly across this period. These data suggest that
cannabis may be a more potent and more important teratogen than tobacco and alcohol.
Figure 2 shows a qualitative choropleth map-graph for
the major CA classes. The yellow zones reflect high incidence and dark blue low incidence.
Supplementary Figs. 1–3 present choropleth maps of
CA incidence by area. Figure 3 shows chromosomal
anomaly incidence for which data is available.

Figure 4 was drawn in Excel and shows the confidence
intervals from CALF for common, intermediate frequency
and rare defects for cannabis-related (CRD) and cannabis
not related (CNRD) defects. For most of the cannabisunrelated defects the confidence intervals overlap. For
most of the cannabis-related defects the confidence intervals either do not overlap, or are near the lower end of the
QLD C.I.’s. Figure 5 expands this list for rare congenital
anomalies and in general terms tends to continue this
trend of non-overlapping confidence intervals or

Fig. 11 Attributable Fraction in the Population for (a) cannabis-related and (b) cannabis-unrelated congenital anomalies
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Fig. 12 P-Values for (a) cannabis-related and (b) cannabis-unrelated congenital anomalies

Fig. 13 Response of five major congenital anomaly classes to (a) Tobacco, (b) Alcohol and (c) cannabis exposure
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confidence intervals at the more extreme end of the range
of the confidence intervals for cannabis-related defects.
Figure 6 compares the QLD and NNSW CA rates
based on the relative rates quoted in the Queensland
CALF file.
Figure 7 compares all the rate ratios of defects using the
quoted rates in the CALF file. Figure 8 makes a similar
comparison with log rates and shows clearly that most of
the cannabis-related defects are more common in NNSW.
CNRD were more common in QLD (23,737/509095,
4.66% v 185/4800, 3.85%, Chi Sq. = 7.002, df = 1, P =
0.0081). CRD were more common in NNSW (394/4800
8.21% v 16,346/509095, Chi Squ. = 376.86, df = 1, P =
6.01 × 10− 84). CRD were more common in NNSW than
CNRD (394/4800 v 185/4800, Prevalence Ratio (PR) = 2.13
(95%C.I. 1.80–2.52), Chi Sq. = 80.284, P = 3.24 × 10− 19).
Supplementary Table 4 lists the PR’s, attributable fraction in the exposed (AFE) and attributable fraction in
the population (AFP) along with their C.I.’s and applicable P-values for all defects and defect classes. They decline from exomphalos (PR = 6.29 (2.94–13.48), AFE =
84.11% (65.95–92.58%) and AFP = 4.71% (0.55–8.69%))
and gastroschisis (PR = 5.85 (3.54–9.67), AFE = 82.91%
(71.75–89.66%) and AFP = 4.34% (1.79–6.82%)).

Figure 9 illustrates the PR’s and C.I.’s for CRD and
CNRD. Figure 10 shows the AFE’s and C.I.’s for CRD
and CNRD. Figure 11 shows the AFP’s and C.I.’s for
CRD and CNRD. P-values are illustrated in Fig. 12.
Figure 13 shows five main defect classes charted
against the use of tobacco, binge alcohol and cannabis.
Rising trends with cannabis seem to apply to CNS, cardiovascular and chromosomal anomalies.
Figure 14 charts all 55 anomalies and anomaly classes
against tobacco use. Figure 15 performs a similar function for binge alcohol.
When a similar exercise is undertaken for cannabis
exposure rising trends appear in several defects in
the top three rows especially in cardiovasculature,
chromosomal anomalies and body wall defects
(Fig. 16).
Supplementary Table 5 lists the regression coefficients
and their significance levels in ascending order of P-values
for cannabis exposure. Supplementary Tables 6 and 7
show this table listed in order of ascending P-values for
tobacco and alcohol respectively.
Supplementary Table 8 lists the significant output of a
linear regression where the defect rate was related to
additive terms of tobacco, binge alcohol use and

Reece and Hulse BMC Pharmacology and Toxicology
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Fig. 15 Congenital Anomaly Rate by Tobacco Use Rate – Ordered by Slopes of Least Squares Regression Lines

cannabis use and includes all P < 0.3. This procedure selects 18 defects for further study. For biological and epidemiological reasons Trisomies 13 and 18 were also
included.
Spatial analysis algorithms do not tolerate missing
data. Hence linear regression was used to investigate 8
defects where spatial data was incomplete. Supplementary Table 8 shows the results of a model interactive in
substances. Cannabis use was identified as being linked
with several defects in this table including Turners
syndrome.
Figure 17 shows the geospatial relationships which
were derived from spdep::poly2nb and then edited to include all geospatial links.
Table 1 gives the results of geospatial regression for a
model with additive terms in drug exposure. These are
spatial error models and are not spatially lagged. In the
additive model series cannabis is independently linked
with all eight anomalies particularly cardiovascular
(ASD, PDA and tetralogy of Fallot, ToF) and chromosomal (ACD and Downs syndrome), gastroschisis and
small intestinal atresia.
Table 2 shows the results of an interactive spatial
model and finds that cannabis is more strongly linked

with these same defects. VSD is now positively associated as is diaphragmatic hernia which have both been
previously noted to be cannabis-associated [19, 20].
A similar exercise is executed for spatially lagged
spatial error (spatially autocorrelated with autocorrelated
error components, SARAR) additive (Table 3) and interactive (Table 4) models with very similar results. In each
case spatial error models were superior to combined
SARAR models, as judged by the log maximum likelihood values, spatial Hausman tests and the largely nonsignificant lambda coefficients.
One notes also that in a number of spatial error
models spatial model parameters rho and lambda are
noted to be highly significant. This therefore justifies the
use of spatial models and also suggests that spatial factors are significant in considering clinical teratological
patterns.
Table 5 summarizes the results of the above spatial
models to facilitate comparisons between the various
substances. The four spatial model structures are listed
across the top of the Table and the various substances
are listed in the rows. One notes that cannabis was independently predictive in 27 of the 36 models compared to
only five each for tobacco and alcohol. Cannabis was

Reece and Hulse BMC Pharmacology and Toxicology
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Fig. 16 Congenital Anomaly Rate by Alcohol Use Rate – Ordered by Slopes of Least Squares Regression Lines

Fig. 17 Geospatial Links Between regions – (a) Edited and (b) Final. Maps were drawn using R package “sf” [15]
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Table 2 Results of geospatial interactive regression by selected congenital anomalies spatial error models
Parameters

Model

Parameter

Estimate (C.I.)

P-Value

Parameters

Value

P-Value

phi

1.01E-02

NA

psi

−3.13E-06

0.9999

rho

−7.64E-01

0.9400

phi

1.05E-02

NA

psi

2.99E-06

1

rho

−4.66E-01

0.2291

ADDITIVE MODELS
spreml(log(Atrial_Septal_Defects) ~ DlyCigs11 + log(RiskAlc11) + Cannabis)
Atrial Septal Defect
Cannabis

0.03 (0.00, 0.06)

0.0305

CHROMOSOMAL Defects
Cannabis

0.04 (0.01, 0.07)

0.0212

Downs Syndrome
Cannabis

0.09 (0.05, 0.13)

2.9E-05

phi

5.57E-02

NA

Binge_Alcohol

−2.02 (−3.35, − 0.69)

0.0029

psi

3.57E-05

0.9999

rho

−6.85E-01

0.0883

phi

1.44E-02

NA

psi

1.78E-05

0.9999

rho

−2.50E-01

0.552

Gastroschisis
Cannabis

0.07 (0.03, 0.11)

0.0030

Hypospadias
−0.07 (−0.13, −0.01)

Cannabis

0.0166

phi

0.0419

0.9972

psi

3.0E-05

0.9999

rho

−0.6292

0.1224

phi

1.01E-02

NA

psi

−9.20E-06

1.0000

rho

−1.0E+ 00

0.0025

phi

1.09E-02

NA

psi

6.74E-05

0.9998

rho

−1.15E-02

0.9776

phi

1.10E-01

0.9963

psi

5.67E-05

0.9998

rho

3.07E-01

0.3382

Patent Ductus Arteriosus
Cannabis

0.03 (0.01, 0.05)

0.0453

Small Intestinal Stenosis / Atresia
Cannabis

0.07 (0.03, 0.11)

0.0001

Tetralogy Fallot
Cannabis

0.09 (0.04, 0.14)

0.0007

INTERACTIVE MODELS
spreml(Atrial_Septal_Defects ~ Tobacco * Binge_Alcohol * Cannabis)
Atrial_Septal_Defect
Binge_Alcohol: Cannabis

−0.58 (−1.12, − 0.04)

0.0376

phi

0.0101

NA

Tobacco: Binge_Alcohol: Cannabis

0.03 (0, 0.06)

0.0417

psi

9.1E-08

1.0000

Tobacco: Cannabis

−0.09 (− 0.18, 0)

0.0423

rho

−0.9960

0.0037

CHROMOSOMAL_Defects
Tobacco: Binge_Alcohol: Cannabis

−0.01 (− 0.01, − 0.01)

0.0007

phi

0.0890

NA

Binge_Alcohol: Cannabis

0.05 (0.02, 0.08)

0.0021

psi

2.2E-05

0.9999
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Table 2 Results of geospatial interactive regression by selected congenital anomalies spatial error models (Continued)
Parameters
Parameter

Model
Estimate (C.I.)

P-Value

Parameters

Value

P-Value

Tobacco: Cannabis

0.02 (0.01, 0.03)

0.0047

rho

−0.9805

0.0058

Tobacco: Binge_Alcohol

0.02 (0, 0.04)

0.0184

Cannabis

7.26 (3.21, 11.31)

0.0004

phi

0.0095

0.9964

Binge_Alcohol

7.33 (3.15, 11.51)

0.0006

psi

−1.7E-07

1.0000

Binge_Alcohol: Cannabis

−2.07 (−3.26, − 0.88)

0.0006

rho

0.9660

<2e-16

Tobacco: Cannabis

−0.22 (− 0.37, − 0.07)

0.0041

phi

0.0571

NA

Diaphragmatic_Hernia

Tobacco: Binge_Alcohol: Cannabis

0.06 (0.02, 0.1)

0.0051

Tobacco

0.17 (0.04, 0.3)

0.0091

Binge_Alcohol: Cannabis

0.03 (0.02, 0.04)

3.4E-05

Binge_Alcohol

−2.33 (−3.7, −0.96)

0.0008

Downs Syndrome

psi

3.6E-05

0.9998

rho

−0.6662

0.0626

phi

0.0144

NA

psi

1.8E-05

0.9999

rho

−0.2503

0.5520

phi

0.0027

NA

Gastroschisis
Cannabis

0.07 (0.03, 0.11)

0.0030

Hypospadias
Tobacco: Cannabis

−0.13 (− 0.22, − 0.04)

0.0062

Tobacco: Binge_Alcohol: Cannabis

0.04 (0.01, 0.07)

0.0084

psi

4.3E-05

0.9999

Tobacco: Binge_Alcohol

−0.35 (− 0.66, − 0.04)

0.0266

rho

−0.2080

0.6705

Tobacco

1.13 (0.11, 2.15)

0.0304

Patent_Ductus_Arteriosus
Cannabis

0.24 (0.01, 0.47)

0.0358

phi

0.0109

NA

Binge_Alcohol: Cannabis

−0.06 (−0.12, 0)

0.0526

psi

1.8E-06

1.0000

rho

−0.9998

0.0022

phi

0.0100

NA

psi

1.3E-07

1.0000

rho

−0.0089

0.9825

phi

0.1102

0.9963

psi

5.7E-05

0.9998

rho

0.3074

0.3382

Small Intestinal Stenosis / Atresia
Cannabis

0.02 (0.01, 0.03)

0.0003

Tetralogy_Fallot
Cannabis

0.09 (0.04, 0.14)

0.0007

Ventricular_Septal_Defect
Tobacco: Cannabis

−0.11 (− 0.21, − 0.01)

0.0328

phi

0.4947

NA

Tobacco: Binge_Alcohol: Cannabis

0.03 (0, 0.06)

0.0372

psi

1.2E-04

0.9997

Cannabis

2.93 (− 0.23, 6.09)

0.0692

rho

−1.0000

0.0306

Binge_Alcohol: Cannabis

−0.85 (−1.79, 0.09)

0.0750

Technical Abbreviations: phi Idiosyncratic component of the spatial error termpsi: individual time-invariant component of the spatial error termrho: spatial
autoregressive parameter, lambda: spatial autocorrelation coefficient
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Table 3 Results of geospatial additive regression by selected congenital anomalies combined spatial error and spatial lag (SARAR)
models
Parameter
Parameter

Model
Estimate (C.I.)

P-Value

Parameters

Value

P-Value

0.04 (0.01, 0.07)

0.0078

phi

0.0706

NA

psi

4.4E-05

0.9999

rho

0.0373

0.9400

lambda

−0.8526

0.0291

Atrial Septal Defect
Cannabis

CHROMOSOMAL Defects
Cannabis

0.04 (0.01, 0.07)

0.0227

phi

0.0072

0.9998

Tobacco

−0.03 (−0.06, 0)

0.0404

psi

2.1E-05

0.9999

rho

0.2018

0.7175

lambda

−0.2621

0.6308

phi

0.0135

0.9994

psi

1.4E-05

1.0000

rho

0.6731

0.0333

lambda

−0.7513

0.0436

Diaphragmatic_Hernia
Cannabis

0.06 (0.01, 0.11)

0.0269

Downs Syndrome
Cannabis

0.09 (0.05, 0.14)

2.7E-05

phi

0.0135

NA

Binge_Alcohol

−2.02 (−3.34, −0.7)

0.0027

psi

−2.0E-05

0.9999

rho

−0.7249

0.1285

lambda

0.0633

0.8845

phi

0.0116

0.9996

psi

−2.6E-05

0.9999

rho

−0.2004

0.7327

lambda

−0.0568

0.9039

Gastroschisis
Cannabis

0.07 (0.02, 0.11)

0.0029

Hypospadias
Cannabis

−0.09 (− 0.16, − 0.03)

0.0034

phi

0.2884

NA

psi

−0.0001

0.9996

rho

0.0213

0.9665

lambda

−0.6716

0.0760

phi

0.1043

0.9957

psi

2.1E-05

0.9999

rho

−0.5223

0.4700

lambda

−0.76625

0.1705

Patent Ductus Arteriosus
Cannabis

0.03 (0, 0.06)

0.0365

Tetralogy Fallot
Cannabis

0.08 (0.04, 0.13)

0.0005

phi

0.1269

NA

psi

−0.0001

0.9998

rho

0.5305

0.1006

lambda

−0.3621

0.4032

phi

0.0068

0.9995

Ventricular Septal Defect
Tobacco

−0.03 (− 0.05, 0)

0.0166

Reece and Hulse BMC Pharmacology and Toxicology

(2020) 21:75

Page 18 of 28

Table 3 Results of geospatial additive regression by selected congenital anomalies combined spatial error and spatial lag (SARAR)
models (Continued)
Parameter
Parameter

Model
Estimate (C.I.)

P-Value

involved in 19 interactive terms compared to ten and 13
for alcohol and tobacco respectively. It follows therefore
that cannabis was involved in 46 terms compared to 15
and 18 for alcohol and tobacco respectively.
Having demonstrated a strong associational relationship between drug exposure and several congenital
anomalies the next issue of importance relates to the
issue of whether the relationship was causal or not. Inverse probability weights were generated and used to derive a dataset pseudorandomized for cannabis exposure.
Data was processed by robust interactive generalized linear modelling functions. As shown in Table 6 cannabis
was significantly related to 18 anomalies either alone or
in interaction with tobacco and alcohol.
This exercise was repeated with (non-robust) mixed
effects modelling as such models in R have standard deviations associated with them, which is required in the
E-values algorithm which follows. As shown in Table 7
similar results were obtained for 11 congenital
anomalies.
It is conceivable that the described relationships were
related to some factor other than the measured covariates. E-Values quantitate the degree of association required of some unmeasured confounder with both
cannabis exposure and the dependent variables to explain away the described effect. One notes that 1.25 is
the value quoted in the literature as the threshold of
interest in sensitivity analyses [21]. Table 8 lists 27 eValues and finds that 21 minimum e-Values were
greater than 1.25 and ranged up to 3.8 × 1030 for geospatial models and up to infinity for mixed effects models,
making uncontrolled confounding unlikely.

Discussion
This investigation presents many intriguing findings.
Despite the several technical shortcomings of this dataset it is fascinating for the details and tantalizing clues
which have been revealed. Importantly most of its major
findings have been confirmed previously in other locations particularly in Colorado, Hawaii, Canada, and USA
and by professional bodies such as AHA, AAP and CDC
lending support to the strength of its principal results [2,
3, 11, 13, 19, 20].
NNSW has higher prevalence rates of the cannabis
related anomalies: neural tube defects; small intestinal

Parameters

Value

P-Value

psi

4.4E-06

1.0000

rho

−0.9832

0.0135

lambda

−0.3843

0.3813

atresia; body wall defects: exomphalos, gastroschisis,
diaphragmatic hernia; the cardiovascular disorders:
ASD, VSD, PDA, tetralogy of Fallot, and transposition
of the great vessels (TxGrVess); and the genetic disorders: all chromosomal disorders, Downs syndrome,
Turners syndrome and trisomy 18. Amongst the defect classes cardiovascular, respiratory, and chromosomal anomalies were elevated. Some of these
associations have been previously reported [3, 4, 22]
and were seen in our unpublished analyses of US
data.
QLD Health data showed that the NNSW CI’s for
CRD’s were mostly non-overlapping or were at the extreme end of the QLD CI’s. CRD’s had higher rate ratios
than CNRD’s.
Rising rates of cardiovascular, gastrointestinal and respiratory defects, and their first principal component
were associated with falling rates of tobacco and alcohol
use but rising cannabis use, just as was found in Colorado and USA [3].
At geospatial and linear regression the cardiovascular
defects ASD, VSD, PDA, ToF, TxGrVess; the chromosomal defects ACD, Downs, Turners, Trisomy 13; the
body wall defects gastroschisis, exomphalos, diaphragmatic hernia; the GI disorders small intestinal atresia
and anal stenosis were all linked with cannabis exposure
and for most cannabis exposure was an independent risk
factor.
Rising rates of cannabis exposure were more strongly
associated with cardiovascular, chromosomal, gastrointestinal and body wall defects than were rising rates of
tobacco or alcohol exposure.
Analysis of this dataset by the formal techniques of
causal inference analysis including inverse probability
weighting and E-Values demonstrated that the described
relationships fulfil the criteria for causal relationships.
These results show a striking concordance with epidemiological series from elsewhere. ASD, VSD, ToF, obstructive urinary disorders, hydrocephalus, anal
anomalies and Downs syndrome were linked with PCE
in a large Hawaiian series [4]. VSD has previously been
linked with PCE [19]. Neural tube defects were noted to
be elevated in a cannabis-related manner in Canada and
Hawaii [4, 11]. ASD, PDA ACD and Downs were seen to
rise in close temporal association with increased
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Table 4 Results of geospatial interactive regression by selected congenital anomalies combined spatial error and spatial lag (SARAR)
models
Parameter
Parameter

Model
Estimate (C.I.)

P-Value

Parameters

Value

P-Value

0.04 (0.01, 0.07)

0.0078

phi

0.0706

NA

psi

4.4E-05

0.9999

rho

0.0373

0.9400

lambda

−0.8526

0.0291

Atrial_Septal_Defect
Cannabis

CHROMOSOMAL_Defects
Tobacco: Cannabis

0.01 (0, 0.02)

0.0142

phi

0.0380

0.9971

Tobacco: Binge_Alcohol: Cannabis

0 (−0.01, 0)

0.0236

psi

2.1E-05

0.9999

rho

−0.9999

0.0256

lambda

0.5894

0.0866

phi

0.0135

0.9994

psi

1.4E-05

1.0000

rho

0.6731

0.0333

lambda

−0.7513

0.0436

Diaphragmatic_Hernia
Cannabis

0.06 (0.01, 0.11)

0.0269

Downs Syndrome
Binge_Alcohol: Cannabis

0.03 (0.01, 0.04)

3.1E-05

phi

0.0158

NA

Binge_Alcohol

−2.33 (−3.69, − 0.97)

0.0008

psi

−2.8E-05

0.9999

rho

−0.7121

0.1372

lambda

0.0716

0.8688

phi

0.0116

0.9996

psi

−2.6E-05

0.9999

rho

−0.2004

0.7327

lambda

−0.0568

0.9039

Gastroschisis
Cannabis

0.07 (0.02, 0.11)

0.0029

Hypospadias
Tobacco: Cannabis

−0.12 (− 0.2, − 0.04)

0.0035

phi

0.2455

NA

Tobacco: Binge_Alcohol: Cannabis

0.03 (0.01, 0.06)

0.0050

psi

−0.0002

0.9994

Tobacco: Binge_Alcohol

−0.33 (− 0.61, − 0.06)

0.0184

rho

0.0263

0.9544

Tobacco

1.09 (0.17, 2.01)

0.0201

lambda

−0.4710

0.1431

Cannabis

0.26 (0.04, 0.49)

0.0208

phi

0.0100

0.9992

Binge_Alcohol: Cannabis

−0.07 (− 0.13, − 0.01)

0.0339

Patent_Ductus_Arteriosus

psi

1.7E-07

1.0000

rho

−0.4196

0.5496

lambda

−0.8473

0.1166

phi

0.1269

NA

psi

−5.2E-05

0.9998

rho

0.5305

0.1006

lambda

−0.3621

0.4032

phi

0.0105

0.9993

Tetralogy_Fallot
Cannabis

0.08 (0.04, 0.13)

0.0005

Ventricular_Septal_Defect
Cannabis

0.05 (0, 0.1)

0.0370
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Table 4 Results of geospatial interactive regression by selected congenital anomalies combined spatial error and spatial lag (SARAR)
models (Continued)
Parameter

Model

Parameter
Tobacco: Cannabis

Estimate (C.I.)

P-Value

Parameters

Value

P-Value

0 (0, 0)

0.0420

psi

4.3E-06

1.0000

rho

−0.9997

0.0360

lambda

−0.2285

0.6320

cannabis use in Colorado [3]. Exomphalos was implicated in animals [23, 24] and in some clinical series including in Queensland [25]. Transposition of the great
vessels has previously been linked with paternal PCE
[26]. Indeed in Canada total CA’s were linked with increased cannabis use after controlling for income and
sociodemographic variables [2].
Many series implicate PCE in gastroschisis aetiology
with a meta-analyzed bivariate O.R. = 4.12 (95%C.I.
3.45–4.91) [4, 27–32]. Our findings PR = 5.85 (3.54–
9.67) contradict those of a 2011 NSW Health report on
gastroschisis in this region [33] which erroneously applied an inflated Bonferroni correction to obviate a significant result. Indeed if the 9 cases reported in NSW
[33] are added to the 16 cases reported in QLD the PR
rises further to 9.13 (6.07–13.72).
Increasing reports from diverse sources indicate that
the evidence is building that cannabis has significant
teratological activities in humans in agreement with animal studies where many severe defects including oedema,
exomphalos, phocomelia, spina bifida, myelocoele, exencephaly and foetal loss were documented [23, 24]. Concordant reports from Hawaii, Colorado and Canada suggest
that the findings reported herein are indeed valid and are
generalizable elsewhere. Given that likely half the NNSW
congenital anomalies are reported internally within NSW
[7] this suggests that the teratological situation in NNSW

is indeed serious. Moreover some of the CA described
here, especially chromosomal defects, are heavily therapeutically aborted antenatally again suggesting that the
situation may well be much worse than our description
suggests. Our analysis strongly implicates cannabis use as
a likely underlying factor.
When one also considers the known epigenetic actions
of cannabis [2, 12, 34–37] and its associations with developmental neurological dysfunction and autism [38–42]
concerns relating to the intergenerational actions of cannabis are heightened.
From both the present data and from similar international analyses a number of important clinical implications arise. Notwithstanding its popular relatively benign
image such analyses indicated not only that the potential
teratological impacts of cannabis are significant but that
they are likely causal in nature. Patients considering
commencing a family should be encouraged to desist
from all drugs prior to conception including cannabis.
Patients who do fall pregnant and who are consuming
cannabis should be encouraged to reduce and cease. Patients wishing to access treatment to assist with such
withdrawal should be provided every encouragement
and assistance to do so. Patients should be warned that
the evidence base for the use of cannabis for most of its
touted clinical indications is weak. Patients should be
advised to avoid cannabis for morning sickness of

Table 5 Summary of geospatial regression model results by substance
Substance

Additive Error
Models

Interactive Error
Models

Additive Error-Lagged
Models

Interactive Error-Lagged
Models

Total
Models

Number of Models

8

10

9

9

36

Cannabis
Independently

8

5

8

6

27

Alcohol
Independently

1

2

1

1

5

Tobacco
Independently

0

2

2

1

5

Cannabis Interactively 0

12

0

7

19

Alcohol Interactively

6

0

4

10

0

Tobacco Interactively

0

8

0

5

13

Total Cannabis

8

17

8

13

46

Total Alcohol

1

8

1

5

15

Total Tobacco

0

10

2

6

18
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Table 6 Robust generalized linear regression models
Parameter

Estimate (95%C.I.)

P-Value

3.46 (0.58, 6.34)

0.0382

Cigarettes: Alcohol

0.45 (0.04, 0.85)

0.0521

Cigarettes

−1.52 (−2.89, − 0.16)

0.0510

Alcohol: Cannabis

−1 (−1.82, − 0.17)

0.0369

PC1
Cannabis

PC1 as Arcsinh
Cannabis

2.89 (0.87, 4.92)

0.0172

Cigarettes: Alcohol

0.39 (0.11, 0.67)

0.0212

Cigarettes

−1.31 (−2.26, − 0.36)

0.0204

Alcohol: Cannabis

−0.85 (− 1.43, − 0.26)

0.0162

Cigarettes: Cannabis

0.1 (0.04, 0.16)

0.0065

Cigarettes: Alcohol

0.55 (0.1, 1)

0.0384

Cigarettes

−1.81 (−3.32, − 0.31)

0.0399

Cigarettes: Alcohol: Cannabis

−0.03 (− 0.05, − 0.01)

0.0068

Alcohol

2.8 (0.84, 4.76)

0.0189

Cannabis

2.6 (1.06, 4.14)

0.0078

Cigarettes: Alcohol: Cannabis

0.02 (0.01, 0.04)

0.0156

Central Nervous System
Anencephalus

CNO

Cigarettes: Cannabis

−0.08 (− 0.14, − 0.02)

0.0194

Alcohol: Cannabis

− 0.79 (−1.25, − 0.34)

0.0067

Cardiovascular System
ASD
Cigarettes: Alcohol: Cannabis

0.12 (0.06, 0.18)

0.0051

Cannabis

8.4 (3.93, 12.88)

0.0062

Alcohol

21.3 (8.16, 34.43)

0.0130

Cigarettes

3.48 (1.07, 5.89)

0.0223

Cigarettes: Alcohol

−1.05 (− 1.78, −0.32)

0.0227

Alcohol: Cannabis

−2.5 (−3.8, −1.19)

0.0056

Cigarettes: Cannabis

−0.4 (− 0.61, − 0.19)

0.0055

VSD
Cigarettes: Alcohol: Cannabis

0.04 (0.01, 0.07)

0.0242

Cannabis

3.38 (0.63, 6.13)

0.0366

Alcohol: Cannabis

−0.98 (−1.79, − 0.18)

0.0381

Cigarettes: Cannabis

−0.13 (− 0.23, − 0.03)

0.0239

6.68 (1.28, 12.07)

0.0416

PDA
Cannabis
Cigarettes: Alcohol: Cannabis

0.09 (0.01, 0.16)

0.0504

Alcohol

16.71 (0.91, 32.5)

0.0719

Cigarettes: Cannabis

−0.29 (− 0.53, − 0.04)

0.0536

Alcohol: Cannabis

−1.98 (−3.55, − 0.4)

0.0392

0.08 (0.01, 0.15)

0.0410

Tetralogy Fallot
Cannabis
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Table 6 Robust generalized linear regression models (Continued)
Parameter

Estimate (95%C.I.)

P-Value

0.02 (0.01, 0.03)

0.0031

Gastrointestinal System
Cigarettes: Alcohol: Cannabis
Cigarettes

0.7 (0.27, 1.13)

0.0090

Cigarettes: Alcohol

−0.22 (−0.35, − 0.09)

0.0081

Cigarettes: Cannabis

−0.07 (− 0.11, − 0.04)

0.0029

0.043 (0.004, 0.081)

0.0463

0.002 (0, 0.005)

0.0692

Small Intestinal Stenosis or Atresia - Additive
Cannabis
Small Intestinal Stenosis or Atresia - IR
Cigarettes: Cannabis
Genitourinary System
Cigarettes: Alcohol: Cannabis

0.01 (0, 0.01)

0.0113

Cigarettes

0.28 (0.08, 0.48)

0.0199

Cigarettes: Alcohol

−0.09 (− 0.15, − 0.02)

0.0195

Cigarettes: Cannabis

− 0.03 (− 0.04, − 0.01)

0.0103

Alcohol: Cannabis

0.65 (0.1, 1.21)

0.0425

Cigarettes: Cannabis

0.08 (0, 0.15)

0.0656

Cigarettes: Alcohol: Cannabis

−0.02 (− 0.04, 0)

0.0614

Cannabis

−2.17 (−4.03, − 0.31)

0.0450

Renal Pelvis Obstruction

Chromosomal Anomalies
Alcohol: Cannabis

0.02 (0, 0.05)

0.0678

Alcohol

−0.82 (−1.62, − 0.02)

0.0684

Cigarettes: Cannabis

0.04 (0.01, 0.08)

0.0380

Cigarettes: Alcohol

0.34 (−0.01, 0.68)

0.0878

Cigarettes

−1.07 (−2.17, 0.02)

0.0862

Cigarettes: Alcohol: Cannabis

−0.01 (− 0.03, 0)

0.0357

GIT

Respiratory
Cigarettes: Cannabis

0.01 (0, 0.02)

0.0927

Cigarettes: Alcohol: Cannabis

0 (−0.01, 0)

0.0497

Cannabis

0.04 (0.01, 0.07)

0.0186

Alcohol

−1.29 (−2.43, − 0.15)

0.0464

Cigarettes

0.21 (0.01, 0.41)

0.0599

Cigarettes: Alcohol

−0.07 (− 0.13, − 0.01)

0.0441

Cigarettes: Alcohol: Cannabis

0.0007 (0.0002, 0.0013)

0.0198

Cannabis

2.71 (0.93, 4.49)

0.0123

Cigarettes: Cannabis

−0.13 (− 0.22, − 0.05)

0.0113

Alcohol: Cannabis

− 0.8 (−1.32, − 0.27)

0.0130

Cigarettes: Alcohol: Cannabis

0.04 (0.01, 0.06)

0.0118

Downs - Additive

Downs - Interactive

Body Wall
Musculoskeletal

Gastroschisis
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Table 6 Robust generalized linear regression models (Continued)
Parameter

Estimate (95%C.I.)

P-Value

Cigarettes

0.11 (0, 0.21)

0.0684

Cannabis

0.27 (0, 0.53)

0.0705

Cigarettes: Cannabis

−0.01 (−0.02, 0)

0.0920

Exomphalos
Cigarettes: Cannabis

0.1 (0.04, 0.16)

0.0118

Cannabis

0.56 (0.14, 0.98)

0.0289

Cigarettes: Alcohol

1.03 (0.21, 1.85)

0.0357

Alcohol

−12.72 (−24.65, −0.8)

0.0661

Cigarettes

−3.2 (−5.78, − 0.61)

0.0386

Cigarettes: Alcohol: Cannabis

−0.04 (− 0.06, − 0.02)

0.0093

Cannabis

0.57 (0.22, 0.92)

0.0092

Cigarettes: Alcohol

0.04 (0, 0.07)

0.0467

Alcohol: Cannabis

−0.12 (−0.2, − 0.04)

0.0128

Face
Cleft Palate / Lip

pregnancy. Heavy cannabis smokers should be warned
that cannabis hyperemesis can mimic hyperemesis
gravidarum.
Moreover since the debate relating to cannabis is typically highly individualistic it seems prudent that medical
professional organizations should partner with public
health agencies and community groups to enlarge the
focus of popular debate from the simply self-referential
to a broader multigenerational perspective.
One major toxicological conclusion which follows directly from these studies is that access to cannabis should
be highly restricted. Indeed such work calls into question the whole issue of the long term advisability of cannabis medicalization / legalization and the sustainability
of such paradigms from a teratological perspective.
The present work has not considered neurological sequalae in the newborn and childhood as has previously been reported to overlap the autistic spectrum disorder and ADHD
and thereby potentially play a major role in the modern
widespread epidemic of these disorders [38–40, 43]. When
such data is factored into consideration the imperatives for
reconsideration and re-evaluation of cannabis legalization
overall are largely increased.
Comparison with alcohol

It is of interest to summarize and compare some of these results directly between cannabis and alcohol as the latter is a
known human foetal teratogen and many learned bodies recommend strongly against tobacco exposure in pregnancy [44].
Figure 13 is a scatterplot of the frequency of the defect
classes compared to the various substances. This Figure
shows clearly that increasing cannabis use is associated
much more strongly with several classes of congenital

anomalies in this dataset than either tobacco or alcohol.
The regression lines in this figure slope upwards much
more strongly for cannabis for CNS defects, cardiovascular defects and chromosomal defects than for either of
the other two substances.
Figures 14, 15 and 16 perform a similar role for each
individual defect by the three substances tobacco, alcohol and cannabis. On the tobacco and alcohol scatterplots most of the regression lines are flat or falling. In
contradistinction on the cannabis scatterplot many of
the first 32 defects appear to be rising with positive
slope. This is quantified in Supplementary Tables 5–7
for cannabis, tobacco and alcohol respectively. The
slopes of the first 8 CA’s are significant and seven slopes
are positive for cannabis. This compared to tobacco and
alcohol where only two and four slopes are significant
respectively and all the slopes are negative.
Table 1 presents the remarkable result that of eight
additive spatial models cannabis is independently predictive for all eight defects and indeed tobacco and alcohol do not appear in final models. Similarly in Table 3
cannabis is independently predictive for eight of nine defects in additive SARAR spatial models. Alcohol only
features in the model for Downs syndrome and its regression coefficient is negative. These differences are
compared directly in Table 5, where as noted cannabis is
implicated in 46 terms compared to 15 for alcohol and
18 for tobacco. Cannabis is implicated independently in
27 terms compared to five each for tobacco and alcohol.
The overall conclusion then from this detailed comparison must be that cannabis is a relatively more
powerful or more potent human teratogen than
alcohol.
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Table 7 Mixed effects model results for selected congenital
anomalies
Parameter

Estimate (95%C.I.)

P-Value

0.053 (0.011, 0.096)

0.0280

0.039 (− 0.004, 0.082)

0.0974

0.079 (0.024, 0.133)

0.0135

Cardiovascular
Atrial_Septal_Defect
Cannabis
PDA
Cannabis
Tetralogy_Fallot
Cannabis
GIT
Cigarettes: Alcohol: Cannabis

0.022 (0.004, 0.041)

0.0362

Cigarettes

0.759 (0.064, 1.455)

0.0581

Cigarettes: Alcohol

−0.219 (−0.424, − 0.013)

0.0637

Cigarettes: Cannabis

−0.082 (− 0.145, − 0.019)

0.0285

Small_Intestinal_Stenosis_Atresia
Alcohol: Cannabis

0.02 (0.008, 0.032)

0.0059

Cigarettes

0.278 (0.043, 0.513)

0.0405

Cigarettes: Alcohol

−0.085 (−0.156, − 0.015)

0.0370

Cigarettes: Alcohol: Cannabis

0.008 (0.002, 0.014)

0.0295

Cigarettes: Cannabis

−0.027 (− 0.048, − 0.006)

0.0289

Cannabis

0.084 (0.019, 0.149)

0.0253

Cigarettes: Alcohol: Cannabis

−0.001 (− 0.002, 0)

0.0701

Cigarettes

0.208 (0.024, 0.392)

0.0464

Cigarettes: Alcohol: Cannabis

0.001 (0, 0.001)

0.0636

Cigarettes: Alcohol

−0.071 (− 0.124, − 0.018)

0.0231

2.686 (0.671, 4.701)

0.0241

GUT_Defects

Chromosomal
Chromosomal

Downs_Syndrome

Body Wall
Musculoskeletal
Cannabis
Cigarettes: Alcohol: Cannabis

0.038 (0.01, 0.067)

0.0236

Alcohol: Cannabis

−0.79 (−1.385, − 0.195)

0.0246

Cigarettes: Cannabis

−0.131 (− 0.228, − 0.034)

0.0228

0.065 (0.016, 0.115)

0.0207

Gastroschisis
Cannabis
Exomphalos
Alcohol: Cannabis

0.042 (0.002, 0.082)

0.0596

Cigarettes: Cannabis

−0.006 (−0.011, 0)

0.0874

Causal inference

A classical criticism of correlative studies is that “correlation does not equal causation.” Judea Pearl, one of the
leading causal statisticians in the world, has described
this criticism as arising from what has been historically
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the “causalophobic” science of statistics [45, 46]. In relation to the present study the following points should be
mentioned. Firstly to observe that an exposure and an
outcome are associated not only statistically but also
across space carries more weight than a simple statistical
association. Secondly inverse probability weighting has
been used in mixed effects and robust structural marginal models with very highly significant results. Inverse
probability weighting is well established in the literature
as transforming an observational study into a pseudorandomized population from which casual inferences
can properly be drawn. Thirdly we have used e-Values
to quantify unmeasured confounding as a notorious
source of extraneous confounding not controlled by
the small number of covariates employed in the
present analysis. E-Values provide a quantitative estimate of the degree of association required of any extraneous factor with both the exposure and the
outcome to explain away the observed effect. Whilst
in the literature e-Values above 1.25 have been stated
to be noteworthy [21] our minimum e-Values ranged
up to infinity in mixed effects models, and up to
5.2 × 10− 13 in spatial models. This finding implies
both the causal nature of the relationship, and also
that the inclusion of further parameters in the model
would not obviate the described effects.
Hence our study demonstrates a causal relationship of
drug and particularly cannabis exposure to several congenital anomalies. The causal relationship in this case is
greatly strengthened by the existence of similar results
from other places in the world as described [2–4, 11, 19]
and the existence of a plethora of biological and epigenetic processes to account for these effects as mentioned
[3, 11–13, 34, 35, 37, 39, 47–50].
It is further noted that the present findings fulfill
all of the qualitative and quantitative Hill criteria for
causality [51].
Our study has several strengths and limitations. Its
strengths include access to whole population data for
Queensland and a significant portion of the NNSW data.
The CA rates and confidence intervals were already provided by QLD Health. The NDSHS is a nationally representative survey conducted every three years and the
authoritative source for most Australian drug use data.
Our analytical strategy combined CA with drug exposure data which is unusual and useful. We have employed
a variety of powerful statistical techniques in this investigation including geospatial analysis, inverse probability
weighting, mixed models and E-Values. Study limitations
relate mainly to the remote location of the NNSW area
close to the Queensland border and the small numbers
of some anomalies reported. Losses due to treatment
within NSW and to stillbirths and prenatal therapeutic
abortion occurring preferentially in CA babies implies
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Table 8 E-values for key regression parameters
Parameter

Table

Estimate (95%C.I.)

RR

E-Values

Mixed Effects Models
lme(Congenital_Anomaly ~ Tobacco * Binge_Alcohol * Cannabis)
Cardiovascular Anomalies
Atrial_Septal_Defect
Cannabis

Table 7

0.053 (0.011, 0.096)

1.15 (1.03, 1.29)

1.57, 1.20

Table 7

0.079 (0.024, 0.133)

1.18 (1.05, 1.32)

1.63, 1.29

Table 7

0.022 (0.004, 0.041)

1.3E+ 160 (3.5E+ 30, 5.1E+ 289)

Infinity, 6.9E+ 30

Table 7

0.02 (0.008, 0.032)

1.05 (1.02, 1.09)

1.29, 1.16

Table 7

0.008 (0.002, 0.014)

Infinity (6.9E+ 169, Infinity)

Infinity, Infinity

Table 7

0.084 (0.019, 0.149)

1.32 (1.06, 1.64)

1.97, 1.33

Table 7

0.001 (0, 0.001)

1.002 (1.000, 1.004)

1.048, 1.009

Table 7

2.686 (0.671, 4.701)

Inf (Inf, Inf)

Infinity, Infinity

Table 7

0.065 (0.016, 0.115)

1.16 (1.04, 1.30)

1.59, 1.24

Table 7

0.042 (0.002, 0.082)

1.07 (1.0045, 1.15)

1.36, 1.07

Tetralogy of Fallot
Cannabis
Gastrointestinal Tract Anomalies
Cigarettes: Alcohol: Cannabis
Small_Intestinal_Stenosis_Atresia
Alcohol: Cannabis
Genitourinary Tract Anomalies
Cigarettes: Alcohol: Cannabis
Chromosomal Anomalies
Cannabis
Downs_Syndrome
Cigarettes: Alcohol: Cannabis
Body Wall Anomalies
Musculoskeletal
Cannabis
Gastroschisis
Cannabis
Exomphalos
Alcohol: Cannabis
Geospatial Models
spreml(Congenital_Anomaly ~ Tobacco * Binge_Alcohol * Cannabis)
Atrial_Septal_Defect
Table 1

−0.58 (−1.12,-0.03)

0.11 (0.13, 0.87)

17.99, 1.54

Tobacco: Binge_Alcohol: Cannabis

Table 1

0.03 (0,0.05)

1.11 (1.00, 1.22)

1.45, 1.07

Tobacco: Cannabis

Table 1

−0.09 (− 0.18,0)

0.71 (0.51, 0.99)

2.17, 1.12

Table 1

0.09 (0.04,0.14)

1.21 (1.08, 1.37)

1.73, 1.39

Tobacco: Cannabis

Table 1

−0.11 (− 0.21,− 0.01)

0.57 (0.34, 0.95)

2.90, 1.27

Tobacco: Binge_Alcohol: Cannabis

Table 1

0.03 (0,0.06)

1.17 (1.01, 1.37)

1.63, 1.11

Table 1

0.24 (0.02,0.47)

2.63 (1.06, 6.51)

4.71, 1.34

Binge_Alcohol: Cannabis

Tetralogy_Fallot
Cannabis
Ventricular_Septal_Defect

Patent_Ductus_Arteriosus
Cannabis
Chromosomal_Defects
Tobacco: Binge_Alcohol: Cannabis

Table 1

-0.01 (− 0.01,0)

0.97 (0.95, 0.99)

1.21, 1.13

Binge_Alcohol: Cannabis

Table 1

0.05 (0.02,0.09)

1.28 (1.09, 1.50)

1.88, 1.42

Tobacco: Cannabis

Table 1

0.02 (0,0.03)

1.07 (1.02, 1.12)

1.35, 1.16

Table 1

0.03 (0.01,0.04)

1.06 (1.03, 1.10)

1.33, 1.22

Downs Syndrome
Binge_Alcohol: Cannabis
Small Intestinal Stenosis / Atresia
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Table 8 E-values for key regression parameters (Continued)
Parameter

Table

Estimate (95%C.I.)

RR

E-Values

Table 1

0.02 (0.01,0.03)

1.06 (1.03, 1.10)

1.31, 1.19

Cannabis

Table 1

7.26 (3.21,11.31)

2.09E+ 09 (1.34E+ 04, 3.27E+ 14)

4.19E+ 09, 2.69E+ 04

Binge_Alcohol: Cannabis

Table 1

−2.07 (− 3.25,-0.88)

2.21E-03 (6.67E-05, 0.74)

9.00E+ 02, 26.56

Cannabis
Diaphragmatic_Hernia

Tobacco: Cannabis

Table 1

−0.22 (− 0.38,-0.07)

0.52 (0.33, 0.81)

3.28, 1.77

Tobacco: Binge_Alcohol: Cannabis

Table 1

0.06 (0.02,0.11)

1.20 (1.05, 1.36)

1.69, 1.30

Table 1

0.07 (0.02,0.11)

1.17 (1.06, 1.31)

1.63, 1.30

Gastroschisis
Cannabis

that the present findings are conservative estimates. The
very high CA rate reported in Queensland has not been
explained despite formal enquiry. The origin of the
NNSW denominator figure is unclear. NSW Mothers
and Babies reports [7] indicate that during 2008–2015
22,084 babies were born in Northern NSW and 30,848
in the central coast region, totalling 52,932 births. These
regions are shown together in our maps. Hence over 11
times the data is available as was used in this analysis if
it can be properly collated between the two jurisdictions
of NSW and Queensland. This would then facilitate geotemporospatial statistical modelling. This proper collation and assembly of data is a top research priority for
future studies. The remote location of NNSW together
with its somewhat trans-jurisdictional status has apparently made such a collation difficult in the past.

Conclusions
In conclusion study data indicate that prenatal cannabis
exposure is a significant and robust covariate of many
congenital anomalies in NNSW particularly affecting the
cardiovascular, chromosomal, body wall and gastrointestinal systems and is highly significant for 10 cannabisrelated defects on geospatial analysis. Close concordance
between these results and previous reports from Hawaii,
Colorado, and Canada and with unpublished USA studies suggest our findings are reliable and generalizable.
On all studies cannabis teratogenesis seems to be more
concerning than the established teratogens tobacco and
alcohol. Fulfillment of the criteria for causal relationships has been demonstrated. Further geospatial epidemiological and basic science research is a priority
given cannabis commercialization. Even beyond the obvious jurisdictional health cost-shifting implications
careful and thorough further investigation of the teratological profile of NNSW by coordinated investigations
between NSW and Queensland over time to current
would appear to be a major international research priority with implications far beyond our shores.
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